NewBiologix

NewBiologix SA is a Swiss biotechnology company located in Lausanne, specializing in the development of technologies for gene and cell therapy manufacturing. Founded in May 2023, the company has secured $50 million in Series A financing to create innovative solutions that address production challenges in gene therapy. Led by co-founders Igor Fisch, Ph.D., and Nicolas Mermod, Ph.D., NewBiologix focuses on engineering cell lines for recombinant adeno-associated virus (rAAV) vector production.

The company offers a range of products, including the Xcell™ Portfolio, which provides insights into rAAV quality, and the Xcell™ Eng-HEK293 Cell Line, designed to streamline rAAV production. Their proprietary DNA integration platform utilizes bioinformatics and advanced R&D to enhance the scalability and cost-effectiveness of viral vector production. NewBiologix aims to make gene therapies more accessible by improving reliability and reducing costs, with plans for beta testing of cell line prototypes by 2024 and commercial availability by 2025.